This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bandhauer K, Nemeth T (1983) Die prognostische Relevanz des primären Differenzierungsgrades und des Erythrozyten-Adhäsionstestes (SRCA) bei oberflächlichen Blasenkarzinomen. Akt Urol 14: 119–124
Baniel J, Grauss D, Engelstein D, Sella A (1998) Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52: 785–789
Brake M, Loertzer H, Horsch R, Keller H (2000) Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163: 1697–1701
Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148: 797–801
Hautmann RE, Paiss T (1998) Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol 159:1845–1850.
Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54: 258–263
Jakse G, Loidl W, Seeber G, Hofstädter F (1987) Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 137: 39–43
Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H (1998) Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34: 67–72
Lehmann J, Retz M, Weining C, Albers P, Frohneberg D, Becker T, Funke P, Sternberg D, Wellek S, Stöckle M, members of the AUO AB 05/95 trial group (2003) Adjuvant cisplatin, methotrexate (CM) versus methotrexate, vinblastine, epirubicin, and cisplatin (MVEC) for locally advanced bladder cancer: A large, randomized, multicenter trial. Proc Am Soc Clin Oncol 22: 391
Lutzeyer W, Rübben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250–252
Mack D, Frick J (1995) Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 45: 958–961
Norming U, Tribukait B, Nyman CR, Nilsson B, Wang N (1992) Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol 148:1420–1426
Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen RW (1983) Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14: 140–143
Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59: 227–231
Pfister C, Lande P, Herve JM, Barre P, Barbagelatta M, Camey M, Botto H (1995) T1 G3 bladder tumors: the respective role of BCG and cystectomy. Prog Urol 5: 231–237
Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139: 283–285
Samodai L, Kiss L, Kolozsy Z, Mohacsi L (1991) The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer. Int Urol Nephrol 23: 559–567
Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R (1987) Radical cystectomy-often too late? Eur Urol 13: 361–367
Summers JL, Falor WH, Ward R (1981) A 10-year analysis of chromosomes in non-invasive papillary carcinoma of the bladder. J Urol 125: 177–178
Sylvester RJ, van der Meijden APM, Lamm DL (2002) Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A metaanalysis of the published results of randomized clinical trials. J Urol 168: 1964–1970
Vicente J, Laguna M, Palou J (1996) The value of conservative treatment in G3T1 bladder tumours. Eur Urol Today 6: 14–18
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Stöckle, M., Lehmann, J. (2005). Das kontrovers diskutierte Tumorstadium pT1G3. In: Blasenkarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26850-2_6
Download citation
DOI: https://doi.org/10.1007/3-540-26850-2_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20504-3
Online ISBN: 978-3-540-26850-5
eBook Packages: Medicine (German Language)